Can tumor necrosis factor alpha blockade predispose to severe babesiosis?
Taiwo
Babafemi
B
Northwestern University, Feinberg School of Medicine, Chicago, Illinois, USA. b-taiwo@northwestern.edu
Lee
Chin
C
Venkat
Deepak
D
Tambar
Siddharth
S
Sutton
Sarah H
SH
D000368:Aged; D000818:Animals; D018501:Antirheumatic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001172:Arthritis, Rheumatoid / Q000188:drug therapy; D001403:Babesia / Q000472:pathogenicity; D001404:Babesiosis / Q000139:chemically induced* / Q000175:diagnosis* / Q000473:pathology; D004198:Disease Susceptibility; D000068800:Etanercept; D006801:Humans; D007074:Immunoglobulin G / Q000009:adverse effects* / Q000627:therapeutic use; D008297:Male; D018124:Receptors, Tumor Necrosis Factor / Q000627:therapeutic use; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
D018501:Antirheumatic Agents; D007074:Immunoglobulin G; D018124:Receptors, Tumor Necrosis Factor; D014409:Tumor Necrosis Factor-alpha; D000068800:Etanercept